Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Total Non-Current Liabilities (2020 - 2024)

Historic Total Non-Current Liabilities for Relay Therapeutics (RLAY) over the last 5 years, with Q4 2024 value amounting to $93.5 million.

  • Relay Therapeutics' Total Non-Current Liabilities rose 1870.36% to $93.5 million in Q4 2024 from the same period last year, while for Dec 2024 it was $93.5 million, marking a year-over-year increase of 1870.36%. This contributed to the annual value of $93.5 million for FY2024, which is 1870.36% up from last year.
  • As of Q4 2024, Relay Therapeutics' Total Non-Current Liabilities stood at $93.5 million, which was up 1870.36% from $84.3 million recorded in Q1 2024.
  • Relay Therapeutics' 5-year Total Non-Current Liabilities high stood at $126.0 million for Q3 2022, and its period low was $36.5 million during Q4 2020.
  • For the 5-year period, Relay Therapeutics' Total Non-Current Liabilities averaged around $83.3 million, with its median value being $81.5 million (2023).
  • Its Total Non-Current Liabilities has fluctuated over the past 5 years, first skyrocketed by 15174.18% in 2022, then tumbled by 3277.49% in 2023.
  • Relay Therapeutics' Total Non-Current Liabilities (Quarter) stood at $36.5 million in 2020, then skyrocketed by 65.25% to $60.4 million in 2021, then skyrocketed by 94.07% to $117.2 million in 2022, then tumbled by 32.77% to $78.8 million in 2023, then grew by 18.7% to $93.5 million in 2024.
  • Its Total Non-Current Liabilities was $93.5 million in Q4 2024, compared to $84.3 million in Q1 2024 and $78.8 million in Q4 2023.